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Introduction
Chondroitin sulfate proteoglycan-4 (CSPG4), also known as high molecular weightmelanoma associated antigen (HMW) and melanoma-associated chondroitin sulfate proteoglycan (MCSP), is a well characterized cell surface proteoglycan first identified on human melanoma cells (1) . Subsequent studies showed it to be highly expressed on other solid tumors such as mesothelioma (2) and triple negative breast carcinoma (3) all of which often show an aggressive clinical course. In contrast, CSPG4 has a restricted distribution in normal tissues (4) .
CSPG4 participates in tumor migration, invasion, angiogenesis, and metastasis (5) . It interacts with α4β1 integrins to directly modulate cell adhesion, motility and metastasis as demonstrated by its ectopic expression in tumor cells (6) . Given its restricted expression in normal tissues, high expression on various types of solid tumors and its role in the biology of tumor cells, CSPG4 is an attractive target for immunotherapy.
CSPG4 has been targeted with monoclonal antibodies (mAbs) in models of melanoma, mesothelioma, and breast carcinoma, resulting in the inhibition of tumor growth and survival in addition to thwarting the metastatic capability of tumor cells (7) . Recent advances in potentiating the antitumor effects of a specific mAb rely on coupling its antigen-binding specificity with the effector function and long-term persistence of T lymphocytes to generate specific chimeric antigen receptors (CARs) (8) (9) (10) . These molecules are obtained by fusing the extracellular antigen-binding domain of the mAb with the intracellular signaling domains derived from the CD3-ζ chain of the T-cell receptor, in tandem to costimulatory endodomains to support survival and proliferative signals (11) (12) (13) . Since CAR-modified T cells function independently of a patient's MHC and can readily be generated for clinical use (14) (15) (16) , the value of targeting CSPG4 with a CAR based-approach is appealing.
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Author Manuscript Published OnlineFirst on December 13, 2013; DOI: 10.1158/1078-0432.CCR- We first validated the expression of CSPG4 in an extensive panel of tumor arrays and normal tissues as well as queried public gene expression profiling datasets of human tumors and confirmed its broad expression. We then generated a CSPG4-specific CAR (CAR.CSPG4) and showed that when expressed by T cells, not only was melanoma effectively targeted in vitro, as previously demonstrated (17) , but antitumor activity was observed in vitro and in vivo against many solid tumors including breast carcinoma, HNSCC and mesothelioma. Redirecting T cells to CSPG4 using CARs may thus represent a robust platform to target multiple solid tumors.
Research. 
Materials and Methods
Cell lines. The previously described SENMA, CLB and P1143 tumor cell lines were generated in our laboratory from melanoma biopsies (18) . MDA-MB-231 was originally obtained from American Type Culture Collection (ATCC) and authenticated by the analysis of short tandem repeat sequences performed at MD Anderson Cancer Center, Texas, USA. UACC-812, PCI-30 and PHI cell lines were provided by Dr Ferrone and these cells, when maintained in culture for several passages, retained the same phenotypic expression of CSPG4 as the early cell passages. Previously described melanoma cell lines PLAODE, NE-18732, NE-18588, NE-8959, NE-4405 and NE-371952 were only used to confirm the expression of CSPG4 in a broad array of melanoma cell lines (18) . All these cells, including SENMA, CLB, and P1143, when blind fashion by the pathologist Dr Michael Ittmann based on both intensity (0-3+) and extent of staining (1-3+). A multiplicative staining score was calculated by multiplying the intensity and extent scores to yield scores on a 10 point scale from 0-9 (19) . In microarrays with multiple cores per patient, the individual scores were averaged to obtain a final score. In some cores, tumor was not identified due to artifacts. In the vast majority of cases, IHC showed uniform staining (3+) within a given core and in most cases cores from different patients were highly concordant. Areas of necrosis or acellular keratin were not included in the scoring. Cases were divided based on staining scores into three groups: negative/weak (0-3), moderate (4-6) or strong (7) (8) (9) .
Generation of the CSPG4-specific CAR and transduction of T lymphocytes. The hybridoma 763.74 was generated from a BALB/c mouse immunized with cultured human melanoma cells (20) . The scFv 763.74 was isolated from the hybridoma (21) and then cloned in frame with the human IgG1-CH 2 CH 3 domains, the CD28 costimulatory endodomain and the CD3ζ chain into the SFG retroviral backbone (CAR.CSPG4), as previously described (22) . The control CAR specific for the CD19 antigen (CAR.CD19) has been previously described (13) .
Transient retroviral supernatant was generated by co-transfection of 293T cells with the RD114 envelope (RDF plasmid), the MoMLV gag-pol (PegPam3-e plasmid) and the retroviral vector, as previously described (23) . Statistical Analysis. In vitro data are presented as mean ± standard deviation (SD) and a paired student's t-test was used to determine statistical significance. The in vivo data are presented as mean ± standard error of the mean (SEM) and a paired student's t-test was used
Research. to identify significant differences between CAR-treated and control-treated groups. Public gene expression profiling datasets of human tumors were queried for CSPG4, including data from The Cancer Genome Atlas (TCGA Data Portal; http://tcga-data.nci.nih.gov/tcga), Bittner multicancer dataset (unpublished, from www.oncomine.org) (26, 27) and GeneAtlas U133A data set (http://niogps.org).
Research. Results CSPG4 is expressed on a variety of solid tumors. As CSPG4 was originally identified as a melanoma associated antigen, we first independently validated its expression using IHC in a melanoma tissue array containing multiple primary cutaneous and visceral melanomas and metastatic lesions. Examples of either strong or negative/low staining are shown in Fig. 1A .
Consistent expression of the antigen was documented in all types of lesions, regardless of their primary or metastatic origin, or their cutaneous and visceral source. We therefore analyzed melanomas as a whole group. Overall, 59% of melanomas showed strong staining and 25% displayed moderate staining (Fig. 1B) . We then extended the analysis to include multiple 
protein expression data, CSPG4 mRNA expression was increased in HNSCC. We also found increased mRNA expression in clear cell renal carcinomas by in silico analysis, and overall, despite some intratumor variability, significant increased mRNA levels in all these tumor types relative to the corresponding normal tissues (Fig. 1D) . Examination of the large Bittner multicancer dataset (www.oncomine.org) confirmed high CSPG4 mRNA expression in melanoma, clear cell renal carcinoma, HNSCC, multiple sarcoma types (chondrosarcoma, leiomyosarcoma, liposarcoma), gastrointestinal stromal tumors, skin, and vulvar squamous cell carcinomas (Supplementary Fig. 1 ). Of note several sarcoma cell lines have been previously reported to express CSPG4 protein (29) . A number of other common malignancies such as colorectal, ovarian, and endometrial carcinoma did not show increased CSPG4 transcripts, consistent with the mRNA expression from the TCGA data sets. CSPG4 protein expression in an array of normal tissues was negative (Supplementary Fig. 2 ). In addition to the normal tissues represented in supplementary figure 2, we evaluated CSPG4 expression on a total of 33 different types of tissues, all of which were negative. Using the public Novartis GeneAtlas (http://biogps.org) and TCGA databases, CSPG4 mRNA expression was observed in a number of normal tissues. However, the levels of expression are remarkably lower than those of cancer tissues (Supplementary Fig. 3 ).
We next examined CSPG4 expression in a series of cell lines from a variety of tumor types analyzed above. Expression of CSPG4 was detected in 8 of the 9 melanoma cell lines screened (Fig. 1E) . Importantly, CSPG4 was detected on tumor cell lines representative of the above identified solid tumors such as mesothelioma (MILL and PHI), HNSCC (PCI-30) and breast cancer [MDA-MB-231 (adenocarcinoma) and UACC-812 (ductal carcinoma)] (Fig. 1F) all consistent with our analysis of human tumor samples.
T lymphocytes expressing the CSPG4-specific CAR are cytotoxic against CSPG4 + tumor cell lines but not against primary normal tissues. To target CSPG4 + tumors we generated a
CSPG4-specific CAR containing the CD28 costimulatory endodomain (CAR.CSPG4) (Fig. 2A) .
T lymphocytes from 4 healthy donors were engineered to express the CAR.CSPG4 using a gamma retroviral vector. Transduction efficiency was 80% ± 3%, and both CD4 and CD8 T cells stably expressed the CAR (26% ± 9% and 51% ± 16%, respectively), as assessed by phenotypic analysis by day 7 of culture (Fig. 2B) . The majority of CAR.CSPG4 + T cells were CD45RO + (76% ± 7%) and a fraction retained CD62L expression (51% ± 7%) and CCR7 (13% ± 2%), indicating that they were mainly composed of effector-memory T cells (Fig. 2C) . The expression of CAR.CSPG4 by T cells was comparable to that obtained with a previously described CD19-specific CAR (CAR.CD19) ( Supplementary Fig. 4 ) (30), which was used as an irrelevant-CAR control population.
Cytotoxic activity of control and CAR.CSPG4 + T cells, after 1-2 weeks of culture, was assessed against K562, to measure natural killer cell-mediated activity, and against the melanoma derived cells lines P1143 (as CSPG4 -target) and SENMA (as CSPG4 + target) (Fig. 1E) at various E:T ratios (Fig. 3A) . CAR.CSPG4 + but not control T lymphocytes significantly lysed the CSPG4 + target (59% ± 5% vs. 11% ± 8% at 20:1 ratio)(p< 0.01), while both CAR.CSPG4 + and control T cells showed minimal activity against K562 (12% ± 9% vs. 13% ± 11%) and the CSPG4 -target (<10% in both cases). The antitumor activity of CAR.CSPG4 + T lymphocytes was also evaluated in a 72 hour co-culture assay ( Fig. 3B and C) . CAR.CSPG4 + and control T lymphocytes were co-cultured with GFP-expressing tumor cell lines at an E:T ratio ranging from 5:1 to 3:1 according to the kinetic growth of each cell line. CAR.CSPG4 + T cells significantly controlled the growth of all CSPG4 + cell lines tested: SENMA (residual tumor cells = 0.1% ± 0.06%), CLB (0.1% ± 0.1%), UACC-812 (6% ± 6%), MILL (3% ± 5%), MDA-MB-231 (3% ± 3%), PHI (4% ± 3%), and PCI-30 (0.5% ± 0.5%), but not of the CSPG4 -target P1143 (residual tumor cells 38% ± 10%). As expected, all tumor cell lines tested rapidly grow in the presence of control T lymphocytes (residual tumor cells for: SENMA = 62% ± 3%, CLB = 70% ± 6%, UACC-812 =
on July 15, 2017. © 2013 American Association for Cancer clincancerres.aacrjournals.org Downloaded from 47% ± 15%, MILL = 50% ± 8%, MDA-MB-231 = 42% ± 11%, PHI = 29% ± 6%, PCI-30 = 17% ± 3%, and P1143 = 45% ± 10%). In all cases, the effects of CAR.CSPG4 + T cells were significantly greater than those of control T cells (from p<0.05 to p<0.001). T cells expressing the control CAR.CD19 showed cytotoxic activity neither against CSPG4 + nor CSPG4 -targets (Supplementary Fig. 4 ). As illustrated in Fig. 3 , commercially available primary normal epithelial cell lines (small airway, kidney and prostate) derived from tissuses found to express low levels of CSPG4 mRNA (Supplementary Fig. 3 ) did not express detectable levels of the protein by flow cytometry (Fig. 3D) , and were not lysed by CAR.CSPG4 + T cells when tested in 51 Cr release assays (Fig. 3E) .
CAR.CSPG4 + T lymphocytes secrete Th1 cytokines and proliferate in response to

CSPG4
+ tumors. Since CAR.CSPG4 contains the CD28 costimulatory endodomain, we studied CAR.CSPG4 + T lymphocyte proliferation in response to CSPG4 + tumor cells using a CFSE dilution assay. When CFSE-labeled control and CAR.CSPG4 + T cells were cultured with irradiated SENMA tumor cells for 96 hours, a significant CFSE dilution occurred for CAR.CSPG4 + T cells, with both CD4 and CD8 T cells proliferating at a higher percentage (66% ± 12% and 68% ± 8%, respectively) compared to control CD4 and CD8 T cells (8% ± 7% and 14% ± 10%, respectively) (p<0.05 and p<0.01, respectively) ( Fig. 4A and B) . T cells transduced with the control CAR.CD19 also containing the CD28 endodomain did not show significant proliferation in response to CSPG4 + targets (Supplementary Fig. 4) . We also evaluated whether the inclusion of a "late" co-stimulatory endodomain, such as 4-1BB, in addition to CD28
(third generation construct) provided these T cells with additional proliferative and cytotoxic activity, but found no further benefits (Supplementary Fig. 5 ).
We finally quantified the IL-2 and IFNγ cytokines released in response to the antigen, by co- (Fig. 4D) . (Fig. 5A) , and this corresponded to improved overall survival (Supplementary Fig.   6 ). Although HNSCC and breast carcinoma tumors were not as aggressive as melanoma in vivo, we observed that in both models CAR.CSPG4 + T lymphocytes controlled tumor growth. By day 30 the size of HNSCC tumors was 19 mm 3 ± 10 mm 3 in treated mice versus 190 mm 3 ± 75 mm 3 in control mice (p<0.001) (Fig. 5B) and the size of breast carcinoma tumors was 28 mm 3 ± 13 mm 3 in treated mice versus 166 mm 3 ± 64 mm 3 in control mice (p< 0.001) (Fig. 5C ).
CAR.CSPG4
Discussion
The involvement in several signaling pathways associated with cell proliferation, survival, migration, and suggested high expression in various types of cancers highlight the critical role that CSPG4 has in promoting tumor growth and simultaneously make it an attractive target for immunotherapy. By IHC, we independently validated CSPG4 protein expression in several solid tumors with poor prognosis, such as melanoma, breast cancer, mesothelioma and HNSCC. In silico analysis of microarray expression data confirmed overexpression of CSPG4 in tumors that we validated by IHC as compared to normal tissues, and also disclosed CSPG4 overexpression in other important malignancies including glioblastoma, clear cell renal carcinoma and sarcomas suggesting that targeting this antigen may have a major impact on a broad array of solid tumors.
Since CSPG4-specific mAbs can control tumor growth of CSPG4 + tumor cells, in both melanoma and breast cancer tumor models (7, 31), we proposed to improve the therapeutic benefits of this antibody-based approach by generating a CAR that targets the CSPG4 molecule. In contrast to mAb-based therapy, CAR-T cells should produce long-lasting effects, as engineered T cells can expand at the tumor site upon antigen stimulation if an appropriate costimulatory endodomain, derived from CD28, CD137 or CD134, is incorporated within the CAR (13, 31) . In contrast to a previous report (21), we found that the CSPG4-specific CAR obtained from the same 763.74 single chain has potent antitumor activity. We traced these striking differences to two critical components we have introduced in our construct. First, the scFv in our CAR is coupled with the CD3-ζ endodomain of the TCR rather than the FcεRI-γ chain, which is known to promote a much weaker and less durable signaling (32, 33) . Second, we incorporated the CD28 costimulatory endodomain within the CAR, to accomplish sustained IL-2 production and proliferation in response to CSPG4 + tumor cells, thus recapitulating
previous observations for other CAR molecules (13) . Of note, the inclusion of a second costimulatory endodomain derived from CD137 did not further improve the function of our CAR in vitro, supporting the concept that there is no single optimal configuration that is applicable to all CAR molecules, but that CAR receptor optimization remains largely empirical and required for each molecule.
The most critical improvement in the field by our work is the applicability of CAR. Fig. 6 ), but conversely are likely to be attributed to an intrinsic limitation of the models, as T cells do not persist long term in these immunodeficient mice (Supplementary Fig. 6 ).
To fully translate this approach, the differential expression of CSPG4 in tumor cells versus normal tissues needs to be ensured in order to limit potential toxicities (36, 37) . We found the 
